Company: TELO
Filing Date: 2025-05-07
Form Type: 8-K
Source: 0001641172-25-008956
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-05-07
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

Telomir
Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential
in Autism and Spasmodic Dysphonia

Telomir
Pharmaceuticals, Inc. (NASDAQ:TELO) (“ Telomir”), a leader in age-reversal science, today announced new preclinical data showing
that its lead oral drug candidate, Telomir-1, reverses multiple hallmarks of cellular decline across several human cell lines. The findings
include improved mitochondrial activity, reduced oxidative stress, restored calcium balance, and protection from toxic metal effects - offering
a mechanistic foundation for the Company’s new research initiatives in autism spectrum disorder (ASD) and spasmodic dysphonia (SD).

The
in vitro studies, conducted in collaboration with SmartAssays, demonstrated Telomir-1’s ability to:

  Improve                                                                                                                                 
  Maintaining                                                                                                                             
  Boost                                                                                                                                   
  Healthy                                                                                                                                 
  Reduce                                                                                                                                  
  Excess                                                                                                                                  
  Restore                                                                                                                                 
  Disrupted                                                                                                                               
  Protect                                                                                                                                 
  Iron                                                                                                                                    

These
results suggest that Telomir-1 may address fundamental cellular stress mechanisms associated with aging and chronic disease.

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                   TELOMIR                                      
  Dated:           By:                       /s/                
                   Name:                     Erez               
                   Title:                    Chief